 |
 |
 |
 |
|
|
|
|
 |
|
|
 |
|
|
|
|
| |
|||||||||||||||||
|
|
|
|
|
|
|
|||||||||||
|
|||||||||||||||||
|
EID
Home | Ahead of Print | Past
Issues | EID Search | Contact
Us | Announcements | Suggested
Citation
Volume 8, Number 8, August 2002 Research Pandrug-Resistant Acinetobacter baumannii Causing Nosocomial Infections in a University Hospital, TaiwanPo-Ren Hsueh,* Lee-Jene Teng,* Cheng-Yi Chen,* Wen-Hwei Chen,* Chong-Jen
Yu,* Shen-Wu Ho,* and Kwen-Tay Luh* |
|
|
|
 |
|
| Back to article | |
|
Figure 1. Annual consumption (gram/patient-day x 1,000) of carbapenems (imipenem and meropenem), extended-spectrum cephalosporins (cefotaxime, ceftroaxone, ceftazidime, and cefepime), ciprofloxacin, aminoglycosides (gentamicin, tobramycin, netilmicin, and amikacin) and percent of isolates of imipenem-resistant and pandrug-resistant Acinetobacter baumannii (PDRAB) at the National Taiwan University Hospital, 1993–2000. |
|
|
|
|
|
EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z |
|
|
This page last reviewed July 1, 2002 |
|
|
Emerging
Infectious Diseases Journal |
|